Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences Q1 revenue falls to $28 million; net loss widens to $112 million

Negative Impact 4 of 5 earnings Written later

Arcus Biosciences reported first-quarter 2025 revenue of $28 million, down from $145 million a year earlier, and a net loss of $112 million, compared with $4 million in the same period of 2024. The company said it expects GAAP revenue of $75 million to $90 million for full-year 2025, and it ended the quarter with $1.0 billion in cash, cash equivalents and marketable securities.

Key points

  • Revenue was $28 million versus $145 million a year earlier; license and development services revenue was $20 million versus $135 million.
  • Net loss was $112 million, or $1.14 per share, versus a net loss of $4 million, or $0.05 per share, in the first quarter of 2024.
  • R&D expenses rose to $122 million from $109 million, driven by early-stage and preclinical program activity.
  • Full-year 2025 GAAP revenue is expected to be between $75 million and $90 million.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECMay 6, 2025, 4:09 PM ET
Accession number0001724521-25-000061

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.